U.S. markets close in 6 hours 28 minutes
  • S&P 500

    4,466.53
    -7.22 (-0.16%)
     
  • Dow 30

    34,698.99
    -52.33 (-0.15%)
     
  • Nasdaq

    15,154.17
    -27.76 (-0.18%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    71.77
    -0.84 (-1.16%)
     
  • Gold

    1,751.50
    -5.20 (-0.30%)
     
  • Silver

    22.67
    -0.13 (-0.57%)
     
  • EUR/USD

    1.1763
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.3670
    +0.0360 (+2.70%)
     
  • GBP/USD

    1.3788
    -0.0009 (-0.06%)
     
  • USD/JPY

    110.0180
    +0.3000 (+0.27%)
     
  • BTC-USD

    47,315.20
    -657.74 (-1.37%)
     
  • CMC Crypto 200

    1,203.77
    -21.77 (-1.78%)
     
  • FTSE 100

    7,036.74
    +9.26 (+0.13%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCIV, BLCT and CRMD

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 28, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Churchill Capital Corp IV (NYSE:CCIV)
Class Period: January 11, 2021 - February 22, 2021
Lead Plaintiff Deadline: August 30, 2021

The CCIV lawsuit alleges that Churchill Capital Corp IV made materially false and/or misleading statements and/or failed to disclose that: (1) Lucid was not prepared to deliver vehicles by spring of 2021; (2) Lucid was projecting a production of 557 vehicles in 2021 instead of the 6,000 vehicles touted in the run-up to the merger with Churchill; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Learn about your recoverable losses in CCIV: http://www.kleinstocklaw.com/pslra-1/churchill-capital-corp-iv-loss-submission-form?id=18051&from=1

Bluecity Holdings Limited (NASDAQ:BLCT)
This lawsuit is on behalf of all persons and entities, other than Defendants, who purchased or otherwise acquired BlueCity American Depositary Shares pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about July 8, 2020.
Lead Plaintiff Deadline: September 17, 2021

The BLCT lawsuit alleges that throughout the class period, Bluecity Holdings Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants had overstated BlueCity's business and financial prospects; (2) the Company was ill-equipped to absorb the costs of becoming a publicly traded company, including IPO- and growth-related costs; (3) as a result of all the foregoing, Defendants had misrepresented the Company's capability for sustainable growth; and (4) as a result, the Offering Documents were materially false or misleading and/or failed to state information required to be stated therein.

Learn about your recoverable losses in BLCT: https://www.kleinstocklaw.com/pslra-1/bluecity-holdings-limited-loss-submission-form?id=18051&from=1

CorMedix Inc. (NASDAQ:CRMD)
Class Period: July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline: September 20, 2021

The CRMD lawsuit alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CRMD: https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=18051&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/657478/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-CCIV-BLCT-and-CRMD